| Antioxidant treatment associated with sildenafil reduces monocyte activation and markers of endothelial damage in patients with diabetic erectile dysfunction: a double-blind, placebo-controlled study. | |
| | |
MedLine Citation:
|
PMID: 17478034 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate the synergic effect of propionyl L-carnitine (PLC) plus sildenafil in reducing monocyte oxidative activity and endothelial dysfunction markers in diabetic patients with erectile dysfunction (ED). METHODS: Thirty-two type 2 diabetic patients with ED (according to the International Index of Erectile Function-5 [IIEF-5]) were randomized to receive PLC (2 g/d) alone (n=8) or combined with sildenafil (50 mg/d twice weekly) (n=8), sildenafil alone (50 mg/d twice weekly) (n=8), or placebo (n=8) in a double-blind, fixed-dose study. Monocyte oxidative activity (stimulation index [SI]), intercellular adhesion molecule-1 [ICAM-1], P-selectin, advanced glycation end product (AGE) levels, Doppler sonography (recording peak systolic velocity [PSV]; end diastolic velocity [EDV]; systolic wave time [SWT]; resistive index [RI]), and IIEF score were evaluated before and after 12 wk of treatment; IIEF-5 was evaluated again 4 wk posttreatment. RESULTS: SI was reduced by treatment with PLC alone or combined with sildenafil (p<0.05). In patients treated with PLC plus sildenafil, a decrease in ICAM-1, P-selectin, and EDV values was observed compared with patients treated with sildenafil alone (p<0.05, p<0.01, p<0.001, respectively). IIEF-5 improved in all patients treated with PLC plus sildenafil or sildenafil alone (p<0.03, p<0.05, respectively). Four weeks posttreatment, patients treated with PLC plus sildenafil maintained the improvement of the IIEF-5 compared with patients on sildenafil alone (p=0.05). In patients on PLC treatment (with or without sildenafil), SI was correlated with IIEF-5 (p<0.001), glycemia with STW (p<0.03), and AGEs with IIEF-5 (p<0.01). CONCLUSION: PLC plus sildenafil was more effective in reducing SI and endothelial dysfunction markers in patients with type 2 diabetes and ED. |
| | |
Authors:
|
Susanna Morano; Elisabetta Mandosi; Mara Fallarino; Alessandra Gatti; Claudio Tiberti; Maurizio Sensi; Loredana Gandini; Barbara Buchetti; Luisa Lenti; Emmanuele Angelo Jannini; Andrea Lenzi |
Related Documents
:
|
2883804 - Voluntary movement dysfunction in huntington's disease and tardive dyskinesia. 17403704 - Estimation of residual glomerular filtration rate in dialysis patients from the plasma ... 16859944 - Lipid peroxidation level and antioxidant enzyme activities in the blood of patients wit... 7579074 - Total body nitrogen as a prognostic marker in maintenance dialysis. 14643474 - Early stage impacts of tonsillectomy on immune functions of children. 18842464 - Atrial fibrillation progression and management: a 5-year prospective follow-up study. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't Date: 2007-04-25 |
Journal Detail:
|
Title: European urology Volume: 52 ISSN: 0302-2838 ISO Abbreviation: Eur. Urol. Publication Date: 2007 Dec |
Date Detail:
|
Created Date: 2007-11-12 Completed Date: 2008-01-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7512719 Medline TA: Eur Urol Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 1768-74 Citation Subset: IM |
Affiliation:
|
Department of Clinical Sciences, "Sapienza" University, Rome, Italy. susanna.morano@uniroma1.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antioxidants / administration & dosage* Biological Markers Carnitine / administration & dosage, analogs & derivatives* Diabetes Mellitus, Type 2 / complications* Double-Blind Method Drug Therapy, Combination Endothelium, Vascular / drug effects* Erectile Dysfunction / drug therapy*, physiopathology Hemoglobin A, Glycosylated / analysis Humans Male Middle Aged Monocytes / drug effects*, metabolism Phosphodiesterase Inhibitors / administration & dosage* Piperazines / administration & dosage* Purines / administration & dosage Reactive Oxygen Species / metabolism Sulfones / administration & dosage* |
| Chemical | |
Reg. No./Substance:
|
0/Antioxidants; 0/Biological Markers; 0/Hemoglobin A, Glycosylated; 0/Phosphodiesterase Inhibitors; 0/Piperazines; 0/Purines; 0/Reactive Oxygen Species; 0/Sulfones; 139755-83-2/sildenafil; 17298-37-2/propionylcarnitine; 541-15-1/Carnitine |
| Comments/Corrections | |
Comment In:
|
Eur Urol. 2007 Dec;52(6):1774-5
[PMID:
17478036
]
Eur Urol. 2007 Dec;52(6):1775-6 [PMID: 17478035 ] |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The kinematic filling efficiency index of the left ventricle: contrasting normal vs. diabetic physio...
Next Document: Sequential extraction for evaluating the leaching behavior of selected elements in municipal solid w...